Castle Biosciences Presents Expanded Data Supporting Use of DecisionDx-Melanoma Test to Inform Sentinel Lymph Node Biopsy Recommendations
FRIENDSWOOD, Texas--(BUSINESS WIRE)--Nov 25, 2019--
Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced the presentation of data from an expanded, multi-center, prospectively tested patient cohort study supporting clinical use of the DecisionDx ® -Melanoma test to inform discussions and recommendations regarding sentinel lymph node biopsy (SLNB), as well as data from a separate multi-center prospective outcomes study.
The poster titled, “Identification of melanoma patients with low risk of sentinel lymph node positivity and favorable prognosis using a 31-gene expression profile (GEP) test,” was presented during the 16 th International Congress of the Society for Melanoma Research in Salt Lake City, Utah.
The data supports the clinical use of DecisionDx-Melanoma test results in combination with clinicopathologic factors to identify patients at low risk of sentinel lymph node (SLN) positivity and that T1-T2 patients identified as low risk by the DecisionDx-Melanoma test had high survival rates. This information can inform patient discussions and recommendations regarding the SLNB surgical procedure in line with national melanoma clinical practice guidelines.
In the expanded, multi-center prospectively tested patient cohort study:
In the multi-center prospective outcomes study:
“The study data support the clinical use of DecisionDx-Melanoma test results, along with clinical features and patient age, to identify a group of patients who have a likelihood of a positive sentinel lymph node of less than 5%, suggesting they may be able to safely avoid the SLNB procedure,” said presenter, David M. Hyams, M.D., Eisenhower Medical Center surgeon, Rancho Mirage, California. “This information can inform patient discussions and recommendations regarding the SLNB surgical procedure in line with national melanoma clinical practice guidelines.”
DecisionDx-Melanoma is a gene expression profile test that uses an individual patient’s tumor biology to predict individual risk of cutaneous melanoma metastasis or recurrence, as well as sentinel lymph node positivity, independent of traditional staging factors, and has been studied in more than 3,900 patient samples. Using tissue from the primary melanoma, the test measures the expression of 31 genes. The test has been validated in four archival risk of recurrence studies of 901 patients and five prospective risk of recurrence studies including more than 780 patients. Prediction of the likelihood of sentinel lymph node positivity has also been validated in two prospective multicenter study cohorts that included more than 2,000 patients. Impact on patient management plans for one of every two patients tested has been demonstrated in four multicenter and single-center studies including more than 560 patients. The consistent performance and accuracy demonstrated in these studies provides confidence in disease management plans that incorporate DecisionDx-Melanoma test results.
More information about the test and disease can be found at www.SkinMelanoma.com.
About Castle Biosciences
Castle Biosciences (Nasdaq: CSTL) is a commercial-stage dermatologic cancer company focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The Company currently offers tests for patients with cutaneous melanoma (DecisionDx ® -Melanoma, DecisionDx ® -CM Seq; www.SkinMelanoma.com ) and uveal melanoma (DecisionDx ® -UM, DecisionDx ® -PRAME and DecisionDx ® -UM Seq; www.MyUvealMelanoma.com ), with products in development for other underserved cancers, the two most advanced of which are focused on patients with cutaneous squamous cell carcinoma, and patients who have a difficult-to-diagnose pigmented lesion. Castle Biosciences is based in Friendswood, Texas (Houston), and has laboratory operations in Phoenix, Arizona. For more information, visit www.CastleBiosciences.com.
DecisionDx-Melanoma, DecisionDx-CM Seq, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UM Seq are trademarks of Castle Biosciences, Inc.
The information in this press release contains forward-looking statements and information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections. These forward-looking statements include, but are not limited to, statements concerning the ability of DecisionDx-Melanoma to identify T1-T2 patients at low risk for SLN positivity, the potential for DecisionDx-Melanoma test results to guide SLNB recommendations and discussionsin line with national melanoma clinical practice guidelines and estimates regarding the reduction in SLNB surgical procedures. The words “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We may not actually achieve the plans, intentions, or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that we make. These forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from those in the forward-looking statements, including, without limitation, the risks set forth in our final prospectus filed with the SEC on July 26, 2019 relating to our Registration Statements on Form S-1 (File Nos. 333-232369 and 333-232796) and our Quarterly Report on Form 10-Q for the quarter ended September 30, 2019, filed with the SEC on November 12, 2019, and in our other filings with the SEC. The forward-looking statements are applicable only as of the date on which they are made, and we do not assume any obligation to update any forward-looking statements, except as may be required by law.
View source version on businesswire.com:https://www.businesswire.com/news/home/20191125005125/en/
CONTACT: Media and Investor Contact:
KEYWORD: TEXAS UNITED STATES NORTH AMERICA
INDUSTRY KEYWORD: SCIENCE OTHER SCIENCE RESEARCH SURGERY ONCOLOGY GENERAL HEALTH HEALTH CLINICAL TRIALS
SOURCE: Castle Biosciences, Inc.
Copyright Business Wire 2019.
PUB: 11/25/2019 07:00 AM/DISC: 11/25/2019 07:00 AM